ARKAY Therapeutics, Logo

(609) 362-6818

Follow Us:LinkedIn

Forefront of Modern Innovative Medicine

Beta Cell Destruction & Restoration

Fluorescence immunostaining of the islets for insulin (beta cell; green) and glucagon (alpha cell; red): Endogenously induced Prostaglandin E2 (Inflammation) dose-dependent destruction of Beta cells in C57BL/6 DIO mice 


Mission Statement

Improve the lifestyle and lifespan of Type 2 diabetes patients by providing durable glycemic control.



RK-01: A Think-Outside-The-Box Approach To Durable Glycemic Control 

Type 2 diabetes continues to be an unmet medical need.

~50% of newly diagnosed patients experience primary failure with Metformin (the current standard of care) and secondary failure with second and third add-on drugs in the United States (Montvida, O. et al. Diabetes Care 2017).

Mitigation of the underlying pathophysiology of progresive deterioration of beta-cell function, the "Core defect" in all patients is underserved by current treatment options.

RK-01 is custom-designed and formulated to prevent primary and secondary failure by reducing the risk of insulin dependence.

Results obtained from animal studies as well as controlled clinical studies support the scientific rationale and the product concept.

Currently raising capital for a human PoC study to evaluate superiority of RK-01 over Metformin. 

Submitted an IND application to the FDA  in Q1-2018.


CEOCFO Magazine

"A 'Beta-cell centric' Triple Combination of Metformin, an Angiotensin II Receptor Type I Blocker (ARB) and a selective Cyclooxygenase-2 Inhibitor show promise of providing long-term glycemic control for Type 2 diabetes patients"

The proposed doses of selective Cyclooxygenase-2 (Cox-2) inhibitor, Celecoxib* are safe for chronic use in patients with cardiovascular disease risk.

“As the founder and innovator, before I could ask others to invest in my company, I wanted to make sure that I take the risk with my money and establish the proof-of-concept, which we have accomplished already”

Dr. Ravi Kumar
CEOCFO MAGAZINE
October 3, 2016 Issue

Read Full Article

*April 25, 2018: The FDA's Arthritis Advisory Committee (AAC) and the Drug Safety and Risk Management Advisory Committee (DSaRM) voted by a large margin (15:5) that  CV safety of Celecoxib is comparable to Naproxen and Ibuprofen.

A New Shift in the Paradigm

"Signaling pathways associated with immune dysregulation, obesity-triggered chronic low-grade inflammation, insulin resistance and cardiovascular disease are intricately intertwined and they are inseparable from each other. For efficient clinical management of insulin resistance, chronic hyperglycemia due to glucose intolerance should not be treated in isolation without treating the causative inflammation. Lowering inflammatory parameters, treating pancreatic beta cell dysfunction, managing hypertension and lowering lipid levels are expected to result in a more rapid improvement in clinical outcomes with optimal glycemic control."

Ravi Kumar, Ph.D.
Founder & CEO

Immune Dysregulation-Inflammation-Insulin Resistance Axis

“I agree that you have an interesting angle and great leadership/SAB advice. There is definitely a lot of unmet medical need in this area and I think that targeting inflammation has a lot of potential. I hope your efforts are highly successful!”

Christopher K. Glass, M.D., Ph.D.
Professor of Cellular & Molecular Medicine
Professor of Medicine

Ben & Wanda Hildyard
Chair in Hereditary Diseases School of Medicine
University of California, San Diego


Striving to End the Epidemic of Type 2 Diabetes

Medicine Tablets

Right now, there are no anti-inflammatory 'Beta-cell-centric' therapies on the market for Type 2 diabetes. Our novel & innovative beta-cell centric product, RK-01 restored efficacy of Metformin in C57BL/6J DIO mice with insulin resistance and pancreatic beta-cell dysfunction. We are on track to bring RK-01 to market by 2020.

MEDICINE
Medicine

ARKAY is advancing the ParamAushadam® (derived from Sanskrit, it means "Perfect Medicine" in English) platform by combining drugs at the appropriate doses along with predetermined modified drug release to achieve optimal therapeutic as well as kinetic synergies.
.

PARAMAUSHADAM®
Handshake

Discover why now is the best time to partner and collaborate with our biopharmaceutical company. ARKAY Therapeutics is focused on setting the standard for medicine and treatment of Type 2 diabetes and related disorders such as NASH by advancing an innovative 'Beta-cell-centric' platform.
.

FOR INVESTORS


Invest in a healthier future by becoming a key stakeholder today at ARKAY Therapeutics

Call (609) 362-6818


About Us

With the numbers and cases of diabetes always on the rise with no end in sight, our biopharmaceutical company in East Windsor, New Jersey, decided to take action and do something about this global epidemic. Today, ARKAY Therapeutics is dedicated to developing and commercializing innovative medicines for Type 2 diabetes and preventing the onset of Type 2 diabetes in prediabetic patients.

More than 370 million people worldwide and 26 million people in the U.S. alone suffer from Type 2 diabetes. The disease is not successfully controlled in almost 50% of patients, according to American Diabetes Association.

The potential impact of our diabetes medicine has enormous medical and financial implications. This is an avenue that investors can’t afford to miss.

Learn More About ARKAY Therapeutics


More Than 30 Years of BioMedical Experience


Contact

Thank you for your interest. For questions or comments, please use the information listed here. We look forward to hearing from you soon.

Phone
(609) 362-6818

Hours of Operation
Reach Us via Email 24 Hours a Day, 7 Days a Week

Service Area
Open to Investors Worldwide

Share